Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

MIRACLE Microneedle Integrated Responsive Approach for Cancer Localized Treatment Execution during Plasmonic Photothermal Multimodal Therapy

Coordinator
Academisch Ziekenhuis Groningen, Netherlands
Runs
2 February 2026 to 1 February 2028
Status
Running
EU funding
€233k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101199787

What the project is doing

In the project's own words, from its summary on CORDIS.

Cancer remains a critical global health challenge, with millions of new cases and deaths reported annually. Traditional treatments like surgery, chemotherapy, and radiotherapy often fall short, causing systemic toxicity, severe side effects, and cancer recurrence, significantly impacting patients' quality of life. The MIRACLE project aims to revolutionize cancer treatment by developing an innovative microneedle (MN) patch for localized, multimodal cancer therapy.

Herein, the multimodal therapy integrates plasmonic photothermal therapy (PPTT), where nanoparticles (NPs) are selectively heated by near-infrared (NIR) radiation to destroy cancer cells, with photodynamic therapy (PDT), which generates reactive oxygen species and chemotherapy involving NIR radiation-triggered drug release to enhance treatment efficacy. However, challenges like limited accumulation of agents at tumor sites, unwanted distribution in healthy organs, and leakage during delivery limit clinical translation.

The MIRACLE project will address these challenges by developing a NIR-responsive MN patch integrated with PPTT-assisted multimodal cancer therapy specifically designed for treating superficial cancers like melanoma. These MN patches, with micron-sized needles, painlessly penetrate the skins outer layer to deliver therapeutic agents directly to the tumor, ensuring localized delivery and release. Upon skin insertion and NIR irradiation, the MN patch will deliver NPs (for PPTT), a photosensitizer (for PDT), and a chemotherapeutic drug, concentrating treatment at the tumor, reducing systemic exposure and minimizing side effects.

The project will validate the MN patch through in vitro, ex vivo, and in vivo studies. MIRACLE project aligns with the EU Mission: Cancers goals of advancing cancer treatment by developing innovative MN patch for localized multimodal cancer therapy and improving patients quality of life via a minimally invasive, patient-compliant approach with fewer side effects.

Topics

Who is involved

OrganisationCityCountryRole
Academisch Ziekenhuis GroningenGroningenNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI